Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?

Abstract

The renin-angiotensin system (RAS) and angiotensin II, in particular, play a central role and have been implicated in the spectrum of cardiovascular disease (CVD), beginning with hypertension, diabetes mellitus, atherosclerosis, myocardial infarction (MI), strokes and heart failure.